Hayward, CA (USA)

Acquired by
Lonza in October 2017, the 58,000 ft2
site, located in Hayward, CA (USA), has been operating as a multiproduct
cGMP facility since 1990. Assets
include 1,000L and 2,000L single-use bioreactors and associated downstream
capabilities.